Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Phase II Clinical Trial; Blinatumomab; Olverembatinib; Lymphoblastic Leukemia; Philadelphia Chromosome Positive
ORIGINAL PAPER
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
WHAT WE KNOW
Phase II Clinical Trial; Blinatumomab; Olverembatinib; Lymphoblastic Leukemia; Philadelphia Chromosome Positive
WATCH NEXT
Expected trial readout: 2031-09-30
EVIDENCE
What the evidence supports so far
Research signals
Classification pending.
What remains unverified
The full methodology, effect size, and limitations still require analyst review.
Company impact remains unverified until a direct economic transmission is established.